DOCSLIB.ORG

(MCI) and Dementias in Your Clinical Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

6/6/18 Assessment, Identification, and Management of Mild Cognitive Impairment (MCI) and Dementias in Your Clinical Practice Mark Hogue, Psy.D. Donald McAleer, Psy.D., ABPP Northshore Neurosciences Overview • MCI • Definitions, Subtypes, Screening/ assessment • Dementias • Definitions, Subtypes, Screening / Assessment • Management of Cognitive issues for the general clinician • Referrals/ treatments • Family • Legal / Driving 1 6/6/18 Erie Times-News June 3, 2018 Dementia and Mild Cognitive Impairment • Globally, the number of people diagnosed with dementia is increasing every year at an alarming rate. There are currently over 46.8 million people living with dementia and this is estimated to rise to 131.5 million people by 2050. (Tozer, 7/5/17) • Dementia • A loss of cognitive processes from a prior level of cognitive processes, as compared to age-mates, and due to a pathophysiological process. • MCI • An intermediate step between normal cognition and dementia • A measurable deficit in at least one domain, absent dementia and showing no appreciable deficit in ADL functioning 2 6/6/18 Mild Cognitive Impairment • Diagnos(c concepts to describe cogni(ve change in aging • Benign senescent forge-ulness (BSF) – Kral, 1962 • Mild Cogni?ve Impairment (MCI) – Reisberg et al., 1982 • Age-Associated Memory Impairment (AAMI) – CooK et al., 1986 • Late-life forge-ulness (LLF) – BlacKford & La Rue, 1989 • Age-Associated Cogni?ve Decline (AACD) – Levy et al., 1994 • Cogni?ve Impairment No Demen?a (CIND) – Graham et al., 1997 • Amnes?c Mild Cogni?ve Impairment (aMCI) – Petersen et al., 1999 • Age Related Cogni?ve Decline (ARCD) – DSM IV • Mild Cogni?ve Disorder (MCD) – ICD-10 • Prodromal AD – Dubois et al., 2010 • MCI due to AD – NIA-AA criteria; Albert et al., 2011 • Mild Neurocogni?ve Disorder (MNCD) – DSM-5 Mild Cognitive Impairment • Typical clinical/cognitive problems in MCI • Changes in memory (more dependent on reminders, notes, diaries; misplacing things; etc.) • More difficulties with multi tasking • Changes in attention and executive functions (more easily distracted; less flexible; new difficulties with problem solving; less skilled or interested in planning ahead (e.g. traveling) • Changes in language (word-finding difficulties) • Changes in visuospatial function • Often slower or more stressed (routines change) • Limited insight can occur (what is their theory?) • Often increase in conflict with significant others (new safety concerns from family members; change of roles in family) • ADLs can be impacted (new difficulties with driving in challenging situations; subtle new problems with managing finances; cog. decline in skills; e.g. bridge, golf etc.) • Holsinger et al., 2007; Lautenschlager & Kurz, 2010; McCarten et al., 2013 Management of SMC and MCI 3 6/6/18 Mild Cognitive Impairment Normal Aging MCI Dementia Mild Cognitive Impairment • Subtypes • Amnestic • Most Common?* ? Precursor to SDAT • Non- Amnestic • Impairment in a single or multiple non-memory domain • Language, executive functioning, spatial skills • Depending: could progress to Fronto-Temporal Dementia (FTD), Vascular Dementia (VD), Primary Progressive Aphasia (PPA), Diffuse Lewy Body Dementia (DLB). *Mark has issues with this! 4 6/6/18 Heterogeneity of MCI & possible multiple etiologies Clinical Presenta-ons Possible E-ologies MCI Degenera-ve Amnes-c Vascular MCI Metabolic Mul-ple Domains Trauma-c MCI Single Psychiatric Non-memory Domain Others? Mild Cognitive Impairment • Rate of progression from MCI to dementia: 2 to 20% • Risk factors: • age, race, lower education • HTN, DM, sleep disorders • Apolipiprotein E- epsilon 4 genotype • h/o CVA and h/o cardiac disease have more chance of amnestic than non- amnestic MCI • Pathology: predominantly, MCI autopsy samples show AD pathology ie, tau distribution in medial temporal lobes 5 6/6/18 The aging process Brain Amyloid-β Burden Is Associated with Disrup9on of Intrinsic Func9onal Connec9vity within the Medial Temporal Lobe in Cogni9vely Normal Elderly Zhuang Song, Philip S. Insel, Shannon Buckley, Seghel Yohannes, Adam Mezher, Alix Simonson, Sarah Wilkins, Duygu Tosun, Susanne Mueller, Joel H. Kramer, Bruce L. Millerand Michael W. Weiner Journal of Neuroscience 18 February 2015, 35 (7) 3240-3247; DOI: hTps://doi.org/10.1523/JNEUROSCI.2092- 14.2015 Alzheimer’s Process: Destruction of Cortex 6 6/6/18 Alzheimer’s Process: Destruc3on of Cortex Agreement of new perspectives • Currently, biomarkers, esp. CSF markers can be used as research tool • POSSIBLY: identifying persons @ risk of progressing to AD • Findings from small # of studies from selected clinical samples cannot be generalized (as yet) to the general population 7 6/6/18 Genetics • MCI is a gene+cally complex condi+on and there are currently no major genes known to be involved. • Each of the disorders that my possibly underlay MCI (Eg: AD, vascular pathology, depression) may par+ally have some gene+c components. • Consequently, different genes could underlie e+ologies, and gene+c, environmental, health history, drug/etoh abuse likely creates even a more complex and heterogeneous picture. Mild Cognitive Impairment • Cogni&ve: • Neuropsychiatric: depression, irritability, anxiety, aggression, apathy, dysphoria • Olfactory changes • Gait slowing: motoric cogni&ve risk 8 6/6/18 Mild Cognitive Impairment • If patient or a close contact • MCI can reflect a pathological voices concern about memory or disease that may progress to impaired cognition, assess for dementia. MCI and not assume the • Assessment can rule out concerns are related to normal reversible cause, help pt and aging family to understand cause of cognitive decline and prognosis Recommenda)ons for General Criteria: MCI • General Criteria for MCI Not normal, not demented (Does not meet criteria (DSM IV, ICD 10) for a dementia syndrome Cognitive Decline - Self and/or informant report - and impairment on objective cognitive tests And/or: -Evidence of decline over time on objective cognitive tests Preserved basic activities of daily living (ADLs) / or minimal impairment in complex instrumental functions. 9 6/6/18 Cognitive Complaint Not normal for age Not demented Cognitive decline Essentially normal functional activities Mild Cognitive Impairment Impairment in Memory? Only in Memory? More than one domain? YES NO YES NO YES NO MULTIDOMAIN MULTIDOMAIN AMNESTIC Single non- MCI MCI MCI memory MCI AMNESTIC Non-AMNESTIC Mild cognitive Impairment • should not rely on historical • Subjective cognitive complaints report alone of subjective alone can result in both over- memory concerns when and under-diagnosis of MCI and assessing for MCI thus are insufficient • To screen for MCI - should use a brief, validated cognitive assessment instrument in addition to eliciting patient and informant history regarding cognitive concerns 10 6/6/18 Mild Cognitive Impairment • Should use validated assessment • Various instruments have tools acceptable diagnos:c accuracy but none is superior to another. • For pts who test positive, perform a more formal clinical • Because brief cogni:ve assessment assessment tests are more sensi:ve than specific, pa:ents who test posi:ve for MCI should then have further assessment Mild Cognitive Impairment • Assess for the presence of • Diagnosing dementia functional impairment related to prematurely can lead to negative cognition before diagnosing of consequences for patients and dementia. families. • Cooking, water running, • Assess for evidence of functional misplacing food/ incidentals, impairment limiting need to replace lost items, independence in daily activities financial management, driving/ • A requirement for all dementia directional issues, medication diagnoses, to help distinguish errors, gets lost in stores between MCI and dementia 11 6/6/18 Mild Cognitive Impairment • Clinicians who themselves lack • Perform a medical evalua<on for the necessary experience should MCI risk factors that are refer these patients to a poten<ally modifiable specialist with experience in • Some cases of MCI cognition are reversible, including medica<on adverse events, • Remember the possible sleep apnea, depression, anxiety disorders, NPH, Infec<on, reversible causes Vitamin B12, D deficiencies, various metabolic disorders (chronic UTIs, chronic infec<ons) Mild Cognitive Impairment •Clinicians should •MCI can improve, perform serial remain stable, or assessments over progress over time, time to monitor for which can change changes in cognitive diagnosis and status approach 12 6/6/18 Assessments for MCI (incomplete lists) • Cognitive Assessment Toolkit • Saint Louis University Mental (Alzheimer’s Association) Status (SLUMS). • General Practitioner Assessment of • Cognistat Cognition (GPCOG) • Memory Impairment Screen (MIS) • Cognistat Assessment System: Web based • Mini-Cog • Cognistat Paper • Informant Questionnaire • Cognistat AcOve Form- • Mini Mental Status Exam (MMSE) • Montreal Cognitive Assessment (MoCA) • Now APP for iPhone Cognitive Assessment Toolkit (Medicare Wellness Visit) 13 6/6/18 Cognitive Assessment Toolkit (Medicare Wellness Visit) Mini Cog Validity and Reliability • Validity and Reliability • The primary validation of the Mini-Cog© was tested in studies of accuracy in detecting the presence of dementia, now termed major neurocognitive disorder. Most studies included mainly individuals with Alzheimer type and mixed degenerative/vascular dementias. The recommended cut score for dementia screening (0-2 = positive; 3-5 = negative) was derived empirically to optimize the balance of sensitivity
Recommended publications
  • Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the Early Diagnosis of Dementia Across a Variety of Healthcare Settings (Protocol)

    Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the Early Diagnosis of Dementia Across a Variety of Healthcare Settings (Protocol)

    Cochrane Database of Systematic Reviews Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings (Protocol) Lees RA, Stott DJ, McShane R, Noel-Storr AH, Quinn TJ Lees RA, Stott DJ, McShane R, Noel-Storr AH, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD011333. DOI: 10.1002/14651858.CD011333. www.cochranelibrary.com Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings (Protocol) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 REFERENCES ..................................... 7 APPENDICES ..................................... 8 DECLARATIONSOFINTEREST . 19 Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of i healthcare settings (Protocol) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Diagnostic Test Accuracy Protocol] Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
  • People with Dementia As Witnesses to Emotional Events

    People with Dementia As Witnesses to Emotional Events

    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: People with Dementia as Witnesses to Emotional Events Author: Aileen Wiglesworth, Ph.D., Laura Mosqueda, M.D. Document No.: 234132 Date Received: April 2011 Award Number: 2007-MU-MU-0002 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. FINAL TECHNICAL REPORT PRINCIPAL INVESTIGATOR: Laura Mosqueda, M.D. INSTITION: The Regents of the University of California, UC, Irvine, School of Medicine, Program in Geriatrics GRANT NUMBER: 2007-MU-MU-0002 TITLE OF PROJECT: People with Dementia as Witnesses to Emotional Events AUTHORS: Aileen Wiglesworth, PhD, Laura Mosqueda, MD DATE: December 23, 2009 Abstract Purpose: Demented elders are often the only witnesses to crimes against them, such as physical or financial elder abuse, yet they are disparaged and discounted as unreliable. Clinical experience with this population indicates that significant emotional experiences may be salient to people with dementia, and that certain behaviors and characteristics enhance their credibility as historians.
  • Frontotemporal Dementia Disease and Frontal and Temporal Variant a Study

    Frontotemporal Dementia Disease and Frontal and Temporal Variant a Study

    Downloaded from jnnp.bmjjournals.com on 17 July 2006 A study of stereotypic behaviours in Alzheimer’s disease and frontal and temporal variant frontotemporal dementia S Nyatsanza, T Shetty, C Gregory, S Lough, K Dawson and J R Hodges J. Neurol. Neurosurg. Psychiatry 2003;74;1398-1402 doi:10.1136/jnnp.74.10.1398 Updated information and services can be found at: http://jnnp.bmjjournals.com/cgi/content/full/74/10/1398 These include: References This article cites 22 articles, 10 of which can be accessed free at: http://jnnp.bmjjournals.com/cgi/content/full/74/10/1398#BIBL 4 online articles that cite this article can be accessed at: http://jnnp.bmjjournals.com/cgi/content/full/74/10/1398#otherarticles Rapid responses You can respond to this article at: http://jnnp.bmjjournals.com/cgi/eletter-submit/74/10/1398 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Journal of Neurology, Neurosurgery, and Psychiatry go to: http://www.bmjjournals.com/subscriptions/ Downloaded from jnnp.bmjjournals.com on 17 July 2006 1398 PAPER A study of stereotypic behaviours in Alzheimer’s disease and frontal and temporal variant frontotemporal dementia S Nyatsanza, T Shetty, C Gregory, S Lough, K Dawson, J R Hodges ............................................................................................................................... J Neurol Neurosurg Psychiatry 2003;74:1398–1402 Objective: To document the prevalence and pattern of stereotypic behaviour in patients with Alzheimer’s dementia and frontal and temporal variants of frontotemporal dementia.
  • Comparing Methods to Evaluate Cognitive Deficits in Commercial Airline Pilots

    Comparing Methods to Evaluate Cognitive Deficits in Commercial Airline Pilots

    Comparing Methods to Evaluate Cognitive Deficits in Commercial Airline Pilots Joshua Potocko, MD/MPH UCSF Occupational and Environmental Medicine Residency 30 Min Background Philosophy Scope Comparisons Evidence Review: Example Questions for the Group BACKGROUND LCDR Joshua R. Potocko, MC (FS/FMF), USN “The views expressed in this presentation reflect the results of research conducted by the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.” Potocko’s 6 Proclamations: Certain baseline cognitive functions decline with age. Within an individual, these declines are difficult to predict. Between individuals, different types of decline are variable. Understanding the following are critically important to aviation safety: Age-related declines Temporary disturbances in cognitive function, Stable (or progressive) baseline disturbances due to injury, illness, disease, medication, and substance use. When does cognitive dysfunction become unsafe? Cognitive Function Typical, Normal, Adequate, Average Cognitive Inefficiency Circadian, Fatigue, Mood, Stress Cognitive Deficiency Injury, Illness, Meds, Substances Cognitive Disability Above plus regulatory decisions => requires safety factor Baseline New Baseline Unfit Period Injury Illness Meds Baseline Progressive Decline Age XX? Permanently Unfit Disease? PHILOSOPHY Research Question: What is the “best” way to evaluate cognitive deficits in airline pilots? Best: historical? expert opinion?...or
  • Insert Title of Research Report

    Insert Title of Research Report

    ARCHIVED - Archiving Content ARCHIVÉE - Contenu archivé Archived Content Contenu archivé Information identified as archived is provided for L’information dont il est indiqué qu’elle est archivée reference, research or recordkeeping purposes. It est fournie à des fins de référence, de recherche is not subject to the Government of Canada Web ou de tenue de documents. Elle n’est pas Standards and has not been altered or updated assujettie aux normes Web du gouvernement du since it was archived. Please contact us to request Canada et elle n’a pas été modifiée ou mise à jour a format other than those available. depuis son archivage. Pour obtenir cette information dans un autre format, veuillez communiquer avec nous. This document is archival in nature and is intended Le présent document a une valeur archivistique et for those who wish to consult archival documents fait partie des documents d’archives rendus made available from the collection of Public Safety disponibles par Sécurité publique Canada à ceux Canada. qui souhaitent consulter ces documents issus de sa collection. Some of these documents are available in only one official language. Translation, to be provided Certains de ces documents ne sont disponibles by Public Safety Canada, is available upon que dans une langue officielle. Sécurité publique request. Canada fournira une traduction sur demande. ________ Research Report _________ Prevalence Rates, Profile, and Outcomes for Federally Sentenced Offenders with Cognitive Deficits Ce rapport est également disponible en français. Pour en obtenir un exemplaire, veuillez vous adresser à la Direction de la recherche, Service correctionnel du Canada, 340, avenue Laurier Ouest, Ottawa (Ontario) K1A 0P9.
  • Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care

    Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care

    Hindawi Publishing Corporation International Journal of Family Medicine Volume 2014, Article ID 649253, 10 pages http://dx.doi.org/10.1155/2014/649253 Research Article Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care Maria M. Johansson,1 Anna S. Kvitting,2 Ewa Wressle,1 and Jan Marcusson1 1 Department of Geriatric Medicine and Department of Clinical and Experimental Medicine, Linkoping¨ University, SE-581 85 Linkoping,¨ Sweden 2 Primary Health Care and Department of Medical and Health Sciences, Linkoping¨ University, SE-581 85 Linkoping,¨ Sweden Correspondence should be addressed to Maria M. Johansson; [email protected] Received 21 October 2013; Revised 8 January 2014; Accepted 12 February 2014; Published 23 March 2014 Academic Editor: Samuel Y. S. Wong Copyright © 2014 Maria M. Johansson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Diagnostic evaluations of dementia are often performed in primary health care (PHC). Cognitive evaluation requires validated instruments. Objective. Toinvestigate the diagnostic accuracy and clinical utility of Cognistat in a primary care population. Methods. Participants were recruited from 4 PHC centres; 52 had cognitive symptoms and 29 were presumed cognitively healthy. Participants were tested using the Mini-Mental State Examination (MMSE), the Clock Drawing Test (CDT), and Cognistat. Clinical diagnoses, based on independent neuropsychological examination and a medical consensus discussion in secondary care, were used as criteria for diagnostic accuracy analyses. Results. The sensitivity, specificity, positive predictive value, and negative predictive value were 0.85, 0.79, 0.85, and 0.79, respectively, for Cognistat; 0.59, 0.91, 0.90, and 0.61 for MMSE; 0.26, 0.88, 0.75, and 0.46 for CDT; 0.70, 0.79, 0.82, and 0.65 for MMSE and CDT combined.
  • Included See Page 24 for More Information

    Included See Page 24 for More Information

    16204 N. Florida Ave. • Lutz, FL 33549 PRSRT STD U.S. POSTAGE PAID Professional Assessment Products Bolingbrook IL Permit # 422 July 2018 Leaving talent assessment Are there more than 10 assessment professionals on your team? to chance? Contact our Sales and National Accounts team for additional benets. See page 22. Identify talent Life is better when Develop employees Grow your business everyone’s included See page 24 for more information. A test that removes barriers is inherently a more In addition, items that show differential item inclusive measure. functioning associated with gender or ethnicity The RIAS-2 affords cultural sensitivity by have been eliminated. eliminating the need to read items in English. Bottom line: The RIAS-2 is culturally sensitive. RIAS-2 For more information, see page 150 Reynolds Intellectual Assessment Scales™, Second Edition or visit parinc.com/RIAS2. July 2018 Looking for something a little more scientic? Add technology and objectivity to the hiring equation. Recruiting is too important to leave to chance. Hiring the wrong person lowers performance and destroys organizational morale. The costs in turnover alone are incredible. Go beyond gut instincts. Let InVista’s talent assessment expertise fortify your company’s recruitment process with science and technology. We make it easy to make the best talent decisions. To learn more, see page 24 or visit invistatalent.com. a division of From the CEO Check out Dear Valued Customers, this catalog’s In our April catalog, we looked back in recognition of PAR’s 40th featured items anniversary. Once again, this is a milestone that we owe to you, our Customers, and we thank you for your unwavering support over the past 40 years.
  • Evidence-Based Guide to Cognitive Screening Measures Guideline

    Evidence-Based Guide to Cognitive Screening Measures Guideline

    SESLHD GUIDELINE COVER SHEET NAME OF DOCUMENT An evidence-based guide to cognitive screening measures TYPE OF DOCUMENT GUIDELINE DOCUMENT NUMBER SESLHDGL/092 DATE OF PUBLICATION March 2021 RISK RATING Low LEVEL OF EVIDENCE National Standard 5: Comprehensive care, minimising patient harm in preventing delirium and managing cognitive impairment REVIEW DATE March 2026 FORMER REFERENCE(S) N/A EXECUTIVE SPONSOR or Director, Allied Health EXECUTIVE CLINICAL SPONSOR AUTHOR Michelle Riashi, Principal Psychologist POSITION RESPONSIBLE FOR Principal Psychologist DOCUMENT [email protected] FUNCTIONAL GROUP(S) Allied Health KEY TERMS Cognition, cognitive screening, dementia, mild cognitive impairment SUMMARY The aim of this document is to provide an evidence- based overview of available cognitive screening tools and assist clinicians to make decisions based on best practice in their use with specific clinical populations. THIS DOCUMENT IS A GUIDE FOR BEST PRACTICE This Guideline is intellectual property of South Eastern Sydney Local Health District. Guideline content cannot be duplicated. Feedback about this document can be sent to [email protected] SESLHD GUIDELINE COVER SHEET An evidence-based guide to cognitive screening measures Section 1 - Background ................................................................................................................................ 3 Section 2 – Revision and Approval History ..............................................................................................
  • The Brief Introduction of Memory Training

    The Brief Introduction of Memory Training

    iii DEDICATION I would like to dedicate this work especially to my wife and daughter, for their undaunted faith in me. v ABSTRACT Background: Cognitive rehabilitation aims to alleviate or ameliorate cognitive deficits that have resulted from traumatic brain injury (TBI). The present study developed and evaluated a computer-assisted memory rehabilitation programme, based on a postulated EE & EL model (enriched environment and errorless learning), and through the use of comprehensive cognitive training principles for persons with TBI so as to improve their impaired memory functions. The efficacy of this computer-assisted memory rehabilitation protocol was evaluated through formative and summative tests. It was hypothesized that that positive treatment effectiveness would be exhibited in the two memory rehabilitation programme respectively (i.e. computer-assisted or CAMG; and therapist-administered or TAMG) but not in a control group (CG). Methods: A prospective pretest and posttest quasi-experimental clinical design research was carried out in two phases, i.e. pilot and main study phase. A pilot study was conducted to test out the usability of the training programmes, validity and reliability of measuring instruments and related training procedures. The pilot study involving 15 subjects with TBI gave evidence of the robust content validity and applicability of the two memory training modes. In the main study, 112 subjects were screened by selection criteria from five hospitals and one rehabilitation centre to participate. There were 28 subjects who dropped out of the study due to various reasons. Eighty-four subjects were randomly assigned into the three groups CAMG (n=30), TAMG (n=24) and CG (n=30) and they had completed 1-month, 20-session training and 1-month follow up.
  • Predicting Dementia of the Alzheimer Type Using Cognistat

    Predicting Dementia of the Alzheimer Type Using Cognistat

    Predicting Dementia of the Alzheimer Type Using Cognistat Matthew Battista, PhD, Siobhan O’Toole, PhD, Stephanie Gaudenti, PhD, Nick Tolchin, MA, Jeff Delarm, MA, and Alycia Barlow, MA Although not as extensively studied or widely used as the Mini Mental State Examination, Cognistat may be a more sensitive tool for cognitive evaluation in elders. These investigators propose Cognistat subscale cutoff scores for differentiating DAT from other types of cognitive impairment in veterans. ementia is a generic term mentia is and increasingly will be a tions for both clinical care and future used to characterize the de- major health problem for our aging research, we conducted a study to velopment of multiple cogni- society, including our veteran popu- develop Cognistat cutoff scores that Dtive deficits that impair such lation. would maximally differentiate DAT intellectual abilities as language, ab- Cognistat, also referred to as the from other forms of cognitive im- stract reasoning, and memory, while Neurobehavioral Cognitive Status pairment in a veteran population. In affecting a person’s relational or occu- Examination, is a testing instru- completing this analysis, our overall pational functioning. Dementia can ment used to screen for and differ- goal was to help establish a demen- be caused by a number of physiologi- entiate between a variety of cognitive tia-specific “fingerprint” that practi- cal conditions, including neurode- disorders, including dementia.3–8 It tioners could further use to identify generative, vascular, traumatic, toxic, provides basic information about a those veterans in need of a more or infectious etiologies. patient’s executive system function- comprehensive evaluation. Dementia of the Alzheimer type ing (through measures of attention (DAT) is the most common form of and abstract reasoning), as well as COGNISTAT AS A SCREENING dementia and is characterized as a information on domains character- TOOL progressive neurodegenerative pro- istically affected by dementia.
  • Mini Mental State Examination and Logical Memory Scores for Entry Into Alzheimer’S Disease Trials Kimberly R

    Mini Mental State Examination and Logical Memory Scores for Entry Into Alzheimer’S Disease Trials Kimberly R

    Chapman et al. Alzheimer's Research & Therapy (2016) 8:9 DOI 10.1186/s13195-016-0176-z RESEARCH Open Access Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials Kimberly R. Chapman1, Hanaan Bing-Canar1, Michael L. Alosco1,2, Eric G. Steinberg1, Brett Martin1,3, Christine Chaisson1,3,4, Neil Kowall1,2,5,6, Yorghos Tripodis1,4 and Robert A. Stern1,2,7,8* Abstract Background: Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM) test are used to determine inclusion in Alzheimer’s disease (AD) clinical trials and diagnostic studies. These screening measures have known psychometric limitations, but no study has examined the diagnostic accuracy of the cutoff scores used to determine entry into AD clinical trials and diagnostic studies. Methods: ClinicalTrials.gov entries were reviewed for phases II and III active and recruiting AD studies using the MMSE and LM for inclusion. The diagnostic accuracy of MMSE and LM-II cutoffs used in AD trials and diagnostic studies was examined using 23,438 subjects with normal cognition, mild cognitive impairment (MCI), and AD dementia derived from the National Alzheimer’s Coordinating Center database. Results: MMSE and LM cutoffs used in current AD clinical trials and diagnostic studies had limited diagnostic accuracy, particularly for distinguishing between normal cognition and MCI, and MCI from AD dementia. The MMSE poorly discriminated dementia stage. Conclusions: The MMSE and LM may result in inappropriate subject enrollment in large-scale, multicenter studies designed to develop therapeutics and diagnostic methods for AD. Keywords: Alzheimer’s disease, Clinical trials, MMSE, Logical Memory, Eligibility, Mild cognitive impairment, Neurodegenerative disease Background puncture, positron emission tomography) [1–3], these Alzheimer’s disease (AD) clinical trials and diagnostic are invasive procedures typically conducted following studies are responsible for the testing and development initial screening methods.
  • HABS Public Data Release 2.0 Non-Imaging Notes A. Common

    HABS Public Data Release 2.0 Non-Imaging Notes A. Common

    HABS Public Data Release 2.0 Non-Imaging Notes A. Common Variables SubjID: Unique random subject identifiers. All measures and all image files are denoted with a SubjID identifier. StudyArc: Collection Designation. Codes the collection cycle associated with the Data, HAB_1.0 is baseline, HAB_2.0 is one year followup, etc… Designations such as HAB_2.6 refer to years.months which would be 18m from baseline. X_SessionDate: Specific Date of collection for a given measure or set of measures, with the prefix denoting the modality associated with the data. Note that dates are blinded. Every subject is assigned a random large integer and all dates for a subject are adjusted by this constant. This will mean that all date will appear to be from the future. All dates are provided in standard SQL format of YYYY-MM-DD (Year-Month-Day) Also note that for accessibility reasons all spreadsheets are provided in .csv format. If you open these spreadsheets in excel be aware that excel will automatically reformat dates and may corrupt date information if the date formatting is not returned to YYYY-MM-DD prior to saving the file. This can be done by highlighting the column of dates (prior to saving for the first time) and then going to Format>Cells>Custom and typing ‘yyyy-mm-dd’ in the Type dialogue box and clicking ‘OK’. HABS Public Data Release 2.0 Non-Imaging Notes B. Demographic variables Time: The amount of time, in years, from the initial baseline assessment. NP_Age: Age at time of Neuropsych assessment (rounded to the nearest quarter year).